Biomarker for Alport Syndrome (BioAlport)

Hematuria-Nephropathy-Deafness Syndrome Clinical Trial

— BioAlport  

Official title:

Biomarker for Alport Syndrome: An International, Multicenter, Observational, Longitudinal Protocol

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02718027
• Other study ID #: BAP 06-2018
• Status: Terminated
• Start date: August 20, 2018
• Est. completion date: December 31, 2022

Study information

• Verified date: February 2023
• Source: CENTOGENE GmbH Rostock
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

International, multicenter, observational, longitudinal monitoring study to identify biomarker/s for Alport syndrome and to explore the clinical robustness, specificity, and long-term variability of these biomarker/s

Description:

Alport syndrome (AS) is a progressive hereditary glomerular disease with the prevalence 1 in 50,000. AS is caused by pathogenic variants in the COL4A3, COL4A4, and COL4A5 genes encoding type IV collagen α3, α4, and α5 chains, respectively. There are three modes of inheritance: X-linked Alport syndrome (XLAS), autosomal recessive AS (ARAS), and autosomal dominant AS (ADAS). Alport Syndrome causes progressive kidney damage. The glomeruli and other normal kidney structures such as tubules are gradually replaced by scar tissue, leading to kidney failure. Boys with Alport Syndrome, regardless of the genetic type, eventually develop kidney failure. These boys often need dialysis or transplantation during their teenage or young adult years, but kidney failure can occur as late as 40-50 years of age in some men with Alport Syndrome. Most girls with the X-linked type of Alport Syndrome do not develop kidney failure. However, as women with Alport Syndrome get older the risk of kidney failure increases. Currently, diagnosis of Alport Syndrome relies on careful evaluation of the patient's signs and symptoms, along with the family history. Hearing and vision should also be tested. The evaluation can also include a blood test, urine tests, and a kidney biopsy to determine Alport Syndrome. A genetic test is crucial to confirm the diagnosis and determine the genetic type of Alport Syndrome. There is no cure for Alport syndrome; however, symptomatic treatment can help relieve symptoms. Kidney transplantation is usually very successful in people with Alport Syndrome and is considered the best treatment when end-stage kidney failure is approaching. The aim of this study to identify biomarker/s for Alport Syndrome and to explore their clinical robustness, specificity, and long-term variability, in the attempt to offer access to earlier diagnosis and treatment monitoring.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 12
• Est. completion date: December 31, 2022
• Est. primary completion date: December 31, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 2 Months to 50 Years

Eligibility

INCLUSION CRITERIA

• Informed consent is obtained from the participant or the parent/ legal guardian.
• The participant is aged between 2 months and 50 years
• The diagnosis of Alport Syndrome is genetically confirmed by CENTOGENE EXCLUSION CRITERIA
• Informed consent is not obtained from the participant or from the parent/ legal guardian
• The participant is younger than 2 months or older than 50 years
• The diagnosis of Alport Syndrome is not genetically confirmed by CENTOGENE

Related Conditions & MeSH terms

• Deafness
• Hematuria
• Hematuria-Nephropathy-Deafness Syndrome
• Nephritis
• Nephritis, Hereditary
• Syndrome

Locations

Country	Name	City	State
Albania	University Hospital Center Mother Teresa	Tirana
Georgia	Department of Molecular and Medical Genetics, Tbilisi State Medical University	Tbilisi
India	Amrita Institute of Medical Sciences & Research Centre	Cochin	Kerala
Lithuania	Rare diseases coordinating centre, Vilnius University Hospital Santaros klinikos	Vilnius
Pakistan	Department of Pediatric Gastroenterology and Hepatology, The Children's Hospital and Institute of Child Health	Lahore
Romania	Emergency Hospital for Children "Louis Turcanu"	Timisoara
Sri Lanka	Lady Ridgeway Hospital for Children	Colombo

Sponsors (1)

Lead Sponsor	Collaborator
CENTOGENE GmbH Rostock

Countries where clinical trial is conducted

Albania,  Georgia,  India,  Lithuania,  Pakistan,  Romania,  Sri Lanka, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Identification of Alport Syndrome biomarker/s	All samples will be analyzed for the identification of biomarker/s via Liquid Chromatography Multiple Reaction-monitoring Mass Spectrometry (LC/MRM-MS) and compared to merged control, in order to establish the disease-specific biomarker/s. The LC/MRM-MS is performed on an ABSciex 6500 triple quadrupole mass spectrometer, coupled with a Waters Acquity UPLC.	36 months
Secondary	Exploring the clinical robustness, specificity, and long-term variability of Alport syndrome biomarker/s	Samples will be analyzed for the identified biomarker candidates via Liquid Chromatography Multiple Reaction-monitoring Mass Spectrometry (LC/MRM-MS) and compared to merged control, in order to establish the disease-specific biomarker/s. The LC/MRM-MS is performed on an ABSciex 6500 triple quadrupole mass spectrometer, coupled with a Waters Acquity UPLC.	36 months

External Links

•   CENTOGENE is a rare disease company focused on transforming clinical, genetic, and biochemical data into medical solutions for patients